Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,924 recruiting studies in this area right now.
By phase
- Not applicable2,025
- Phase 21,074
- Phase 1791
- Phase 1/Phase 2480
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama157
- Maryland152
- Arizona126
- Florida104
- Massachusetts104
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,924 total
- NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+ - NCT06558604RecruitingPhase 2
Study of glofitamab with venetoclax for high-risk mantle cell lymphoma
This trial tests a new combination of drugs (glofitamab plus venetoclax, with or without zanubrutinib) for people with mantle cell lymphoma that is either newly diagnosed with high risk features, or has come back or not responded to earlier treatments. The goal is to see if these targeted therapies can improve outcomes.
BrugesAges 18–79 - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT06561880RecruitingPhase 1/Phase 2
Three-drug combo for FLT3-mutated AML
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
Boston, MassachusettsAges 18 years+ - NCT06552559RecruitingPhase 1/Phase 2
Selinexor plus ICE chemo for brain-involved B-cell lymphoma
This trial tests a new drug, selinexor, combined with standard ICE chemotherapy for patients whose B-cell non-Hodgkin lymphoma has spread to the brain or spinal cord. It aims to see if adding selinexor improves treatment results.
SeoulAges 18 years+ - NCT06566742RecruitingPhase 2
Olutasidenib for IDH1-mutated blood disorders
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
Miami, FloridaAges 18 years+ - NCT06563596RecruitingPhase 2
Study of epcoritamab, zanubrutinib, and rituximab for relapsed lymphoma
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06562777Recruiting
How symptoms differ between men and women during immunotherapy
This study looks at how symptoms during immunotherapy (a cancer treatment that boosts your immune system) may differ between men and women. Researchers will follow people with cancer who are starting immunotherapy to see if men and women report different side effects.
Portland, OregonAges 18 years+ - NCT06561152RecruitingPhase 1/Phase 2
Tagraxofusp plus low-intensity chemo for CD123+ AML
This trial tests a drug called tagraxofusp combined with a gentle chemotherapy regimen for people whose acute myeloid leukemia (AML) has come back or not responded to an initial venetoclax-based treatment. The study focuses on patients whose leukemia cells have a protein called CD123 on their surface.
Palo Alto, CaliforniaAges 18 years+ - NCT06557421RecruitingPhase 2
Stopping venetoclax and azacitidine in AML remission
This trial tests whether it's safe to stop the combination of venetoclax and azacitidine (VEN-AZA) in people with AML whose cancer has completely disappeared and who have no detectable leukemia cells left. If you've been on VEN-AZA for about a year and are in deep remission, this study may help you avoid unnecessary treatment.
MarseilleAges 18 years+ - NCT06559033Recruiting
Gene study for multiple myeloma or MGUS patients
This study looks for certain gene changes (GBA/PSAP) in people with multiple myeloma or MGUS. It aims to understand if these genes are linked to the disease, which may help guide future treatments.
RouenAges 18 years+ - NCT06555939Recruiting
Resilience program for teens and young adults with sickle cell disease
This study tests a program called PRISM that helps teens and young adults with sickle cell disease build resilience and manage stress, anxiety, or depression. You may be eligible if you have sickle cell disease and feel down or worried.
Boston, MassachusettsAges 8–25 - NCT06560164Recruiting
Comparing blood transfusion levels in ECMO patients
This trial tests whether giving more or fewer red blood cell transfusions is better for adult patients on ECMO (a machine that helps your heart and lungs work). The goal is to find the best transfusion approach to improve outcomes.
Vienna, State of ViennaAges 18 years+ - NCT06350994Recruiting
Early Heart Check After CAR-T Cell Treatment
This study checks your heart function early after CAR-T cell cancer treatment. It uses a quick heart ultrasound to look for changes soon after the infusion.
ParisAges 18 years+ - NCT06387030Recruiting
EoE biopsy study during endoscopy
This trial looks at taking a small tissue sample during a routine endoscopy to better understand eosinophilic esophagitis (EoE). It may help doctors learn how to diagnose and track EoE more easily.
ParisAges 2–17 - NCT06403163Recruiting
Transfusion monitoring during anesthesia
This trial looks at patients who received a drug or product to help with bleeding (hemostasis) during anesthesia. It aims to understand how these products are used and if they are safe.
AnderlechtAges Any age - NCT06533098RecruitingPhase 3
Nipocalimab vs IVIG for FNAIT in pregnancy
This study tests a new medicine called nipocalimab compared to standard IVIG treatment for pregnant women who are at risk of a serious condition where the mother's antibodies attack the baby's platelets (FNAIT). The goal is to see if nipocalimab can prevent complications like bleeding in the baby.
Birmingham, AlabamaAges 18–45 - NCT06534060RecruitingPhase 2
Testing MB-105 for CD5 positive T-cell lymphoma
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
San Diego, CaliforniaAges 18 years+ - NCT06539182RecruitingPhase 2
DZD8586 for relapsed or refractory CLL/SLL
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
Hefei, AnhuiAges 18 years+ - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT06548152Recruiting
Quality of life for CLL patients on acalabrutinib
This study looks at quality of life in people with CLL who are taking acalabrutinib for the first time. It uses data already collected from a real-world database to see how patients feel and function.
Saint-AffriqueAges Any age - NCT06534021RecruitingPhase 1
Study of IASO-782 for autoimmune blood disorders
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
Wuhan, HubeiAges 18–65 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,924 recruiting hematology studies from the U.S. registry right now, out of 7,354 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.